title: Effects of ergotamine on myocardial blood flow in migraineurs without evidence of atherosclerotic coronary artery disease.
abstract: The effects of intravenous ergotamine (0.25 mg) on basal and hyperemic (dipyridamole) myocardial blood flow (MBF), measured with positron emission tomography and H2(15)O, were assessed in 15 migraineurs in a double-blind, randomized, placebo controlled, crossover study. Ergotamine produced a 27% reduction in hyperemic MBF (2.62 +/- 0.11 vs 3.72 +/- 1.05 ml x min(-1) x g(-1); p <0.05), a 31% reduction in the coronary vasodilator reserve (1.81 +/- 0.50 vs 2.71 +/- 1.15; p <0.01), and a 55% increase in minimal coronary resistance (42.2 +/- 15 vs 26.7 +/- 8 mm Hg x min x ml(-1) x g(-1); p <0.001), suggesting vasoconstriction of the coronary microcirculation.
authors.affiliation: MRC Cyclotron Unit, Imperial College School of Medicine, Hammersmith Hospital, London, United Kingdom.
authors.forename: T
authors.initials: T
authors.lastname: Gnecchi-Ruscone
authors.forename: R
authors.initials: R
authors.lastname: Lorenzoni
authors.forename: D
authors.initials: D
authors.lastname: Anderson
authors.forename: N
authors.initials: N
authors.lastname: Legg
authors.forename: D
authors.initials: D
authors.lastname: Tousoulis
authors.forename: P D
authors.initials: PD
authors.lastname: Winter
authors.forename: A
authors.initials: A
authors.lastname: Crisp
authors.forename: P G
authors.initials: PG
authors.lastname: Camici
mesh_terms: D000368:Aged; D003326:Coronary Circulation / Q000187:drug effects*; D004311:Double-Blind Method; D004878:Ergotamine / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008881:Migraine Disorders / Q000503:physiopathology*; D014055:Tomography, Emission-Computed; D014662:Vasoconstrictor Agents / Q000494:pharmacology*
chemical_list: D014662:Vasoconstrictor Agents; D004878:Ergotamine